Name: 글로벌 시장 동향
SKU: CD4199
Availability: InStock

보고서 요약(국문)

개요
글로벌 클라미디아 감염 진단 시장은 2023년 YY백만 달러에 도달했으며, 2024년부터 2031년까지 연평균 성장률(CAGR) YY%로 성장하여 2031년에는 YY백만 달러에 이를 것으로 예상됩니다.
클라미디아는 박테리아에 의해 발생하는 흔한 성병(STI)입니다. 클라미디아 감염은 치료 및 완치가 가능하지만, 증상이 미미한 경우가 많습니다. 클라미디아는 가능한 한 빨리 치료받는 것이 중요합니다. 치료하지 않고 방치할 경우 심각한 합병증을 유발하고 생식 기관에 영구적인 손상을 초래할 수 있습니다.
시장 동향: 성장 동인 및 제약 요인
정부 정책 증가
영국의 국가 클라미디아 검진 프로그램(NCSP)과 같은 정부 정책은 시장 성장을 더욱 촉진합니다. 이러한 정책은 고위험군을 대상으로 신속한 치료와 지역 사회 내 검사 확대에 중점을 두고 있습니다.

그러나 성병 검사에 대한 사생활 보호 우려와 사회적 낙인은 시장 성장을 저해하는 요인으로 작용합니다. 이러한 요인으로 인해 개인들이 검사를 꺼릴 수 있기 때문입니다. 이러한 어려움에도 불구하고, 높은 유병률, 조기 발견 및 치료에 대한 인식 증가, 그리고 진단 기술의 발전은 시장 성장을 지속적으로 견인하고 있습니다.

저소득 및 중소득 국가에서의 클라미디아 진단 검사에 대한 정보 부족

저소득 및 중소득 국가에서는 클라미디아 감염 진단 시장에 대한 정보 부족, 자발적 검진에 대한 사회적 낙인, 그리고 성병에 대한 부정적인 사회적 인식으로 인해 어려움이 있습니다. 이는 진단되지 않은 감염 사례로 이어지고, 사생활 보호 및 사회적 지위에 대한 우려로 시장 성장을 저해합니다.

본 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
글로벌 클라미디아 감염 진단 시장은 검사 유형, 감염 유형, 최종 사용자 및 지역별로 세분화됩니다.

검사 유형 부문에서 핵산 증폭 검사(NAAT)는 클라미디아 감염 진단 시장 점유율의 약 47.3%를 차지했습니다.
NAAT는 클라미디아 트라코마티스 감염 진단 및 모니터링에 가장 권장되는 방법입니다. 이 분자 검사는 생체 시료에서 질병의 유전 물질인 DNA를 검출합니다. 다른 검사보다 민감도와 특이도가 높으며, 남녀 모두의 질 면봉과 소변 검체로 검사가 가능하여 여성의 경우 골반 검사가 필요하지 않습니다.
예를 들어, 2022년 3월 미국 식품의약국(FDA)은 의원, 지역 사회 기반 클리닉, 응급 진료소 및 기타 최종 사용자를 포함한 현장 진료 환경에서 Binx Health IO CT/N 검사를 허용한다고 발표했습니다.

지리적 분석
북미는 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
북미는 FDA 승인, 높은 클라미디아 감염률, 주요 업체들의 신제품 개발 등 여러 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
예를 들어, 2023년 11월 미국 식품의약국(FDA)은 LetsGetChecked의 Simple 2 Test에 대한 판매 승인을 otorg했습니다. 이는 가정에서 검체를 채취하여 클라미디아와 임질을 진단하는 최초의 자가 진단 키트입니다. FDA 승인 이전에는 병원에서 검체를 채취하여 진단하는 검사만 사용 가능했습니다.

시장 세분화
검사 유형별
• 핵산 증폭 검사(NAAT)
• 배양 검사
• 직접 형광 항체 검사
• 혈청 검사
• 기타
감염 유형별
• 생식기 클라미디아 감염
• 직장 클라미디아 감염
• 안구 클라미디아 감염
최종 사용자별
• 병원
• 진단 센터
• 전문 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche 등이 있습니다. Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA, Becton, Dickinson and Company, Danaher Corporation (Cepheid), Savyon Diagnostics Ltd, Trinity Biotech Plc 등이 있습니다.
주요 개발 사항
 2024년 5월, Sherlock Biosciences는 자사의 신속 일반의약품(OTC) 성병 검사 키트를 평가하는 PROMISE 임상 시험에 첫 번째 환자를 등록했습니다. 이 분자 검사는 음경 요도구 또는 질 면봉을 통해 자가 채취한 DNA와 RNA를 분석하여 클라미디아 트라코마티스와 임균의 존재 여부를 검사합니다.

 2023년 3월, 미국 식품의약국(FDA)은 여성의 클라미디아 트라코마티스, 임균, 질편모충류에 의한 성병(STI) 진단을 위한 중합효소 연쇄 반응(PCR) 검사인 비스비(Visby) 의료 성 건강 검사를 승인했습니다.

보고서 구매 이유:

• 검사 유형, 감염 유형, 최종 사용자 및 지역별 글로벌 클라미디아 감염 진단 시장 세분화를 시각화하고 주요 상업 자산 및 업체들을 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 클라미디아 감염 진단 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 엑셀 파일을 제공합니다.

글로벌 클라미디아 감염 진단 시장 보고서는 약 64개의 표, 61개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Chlamydia Infection Diagnostics Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
Chlamydia is a common sexually transmitted infection (STI) caused by bacteria. Chlamydia infections are treatable and curable. However, its symptoms are often unnoticeable. It’s important to receive treatment for chlamydia as soon as possible. Left untreated, chlamydia can lead to serious complications and cause permanent damage to your reproductive organs.
Market Dynamics: Drivers & Restraints
Rise in government initiatives
Government initiatives, such as the National Chlamydia Screening Program (NCSP) in the UK, further drive the market's growth. These initiatives target high-risk individuals, focusing on rapid treatment and expanded testing in community settings.
However, privacy concerns and societal stigma surrounding STD testing limit market growth, as individuals may be hesitant to undergo testing due to these factors. Despite these challenges, the high prevalence, growing awareness of early detection and treatment, and advancements in diagnostic technologies continue to drive the expansion of the market.

Lack of knowledge of chlamydia diagnostic tests in low and middle-income countries

The chlamydia infection diagnostics market faces challenges in low and middle-income countries due to lack of knowledge, stigma associated with voluntary screening, and negative social perception of sexually transmitted diseases (STDs). This leads to undiagnosed infections and limits the market's growth due to concerns about privacy and social status.

For more details on this report – Request for Sample
Segment Analysis
The global chlamydia infection diagnostics market is segmented based on test type, infection Type, end-user and region.
The Nucleic Acid Amplification Test (NAAT) from the test type segment accounted for approximately 47.3% of the chlamydia infection diagnostics market share
The Nucleic Acid Amplification Test (NAAT) from the test type segment accounted for approximately 42.3%. The Nucleic Acid Amplification Test (NAAT) is the most recommended method for diagnosing and monitoring chlamydia trachomatis infection. This molecular test detects DNA, the genetic material of the disease, in biological samples. It is more sensitive and specific than other tests and can be performed on vaginal swabs and urine from both men and women, eliminating the need for a pelvic exam in women.
For instance, in March 2022, the United States Food and Drug Administration (FDA) announced that it would allow the Binx Health IO CT/N assay at point-of-care settings in physician offices, community-based clinics, urgent care settings, and other end users.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the FDA grants, high prevalence of chlamydia infection among individuals and new product developments by the key players and others help the region to have highest market share during the forecast period.
For instance, in November 2023, the U.S. Food and Drug Administration granted marketing authorization to LetsGetChecked for the Simple 2 Test. This is the first diagnostic test for chlamydia and gonorrhea with at-home sample collection to be granted marketing authorization. Prior to the authorization, the only cleared tests for either condition were used with samples collected at the point of care, such as a doctor’s office.
Market Segmentation
By Test Type
• Nucleic Acid Amplification Test (NAAT)
• Culture Tests
• Direct Fluorescent Antibody Test
• Serology Tests
• Others
By Infection Type
• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection
By End-User
• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA, Becton, Dickinson and Company, Danaher Corporation (Cepheid), Savyon Diagnostics Ltd, Trinity Biotech Plc among others.
Key Developments
 In May 2024, Sherlock Biosciences enrolled its first patient in the PROMISE trial which evaluates the company’s rapid over-the-counter (OTC) test for sexually transmitted infections (STIs). The molecular test analyses DNA and RNA which is self-collected through penile meatal or vaginal swabs to test for the presence of chlamydia trachomatis and Neisseria gonorrhoea.
 In March 2023, The Food and Drug Administration (FDA) cleared the Visby Medical Sexual Health Test, a polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.

Why Purchase the Report?
• To visualize the global chlamydia infection diagnostics market segmentation based on test type, infection type, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the chlamydia infection diagnostics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global chlamydia infection diagnostics market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Infection Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in government initiatives
4.1.1.2. Rise of advancements in diagnostic kits
4.1.2. Restraints
4.1.2.1. Lack of knowledge of chlamydia diagnostic tests in low and middle-income countries
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Test Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
7.1.2. Market Attractiveness Index, By Test Type
7.2. Nucleic Acid Amplification Test (NAAT) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Culture Tests
7.4. Direct Fluorescent Antibody Test
7.5. Serology Tests
7.6. Others
8. By Infection Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
8.1.2. Market Attractiveness Index, By Infection Type
8.2. Genital Chlamydia Infection*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Rectal Chlamydia Infection
8.4. Ocular Chlamydia Infection
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Specialty Clinics
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Bio-Rad Laboratories, Inc*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Abbott Laboratories
12.3. F. Hoffmann-La Roche Ltd
12.4. Hologic, Inc
12.5. Quidel Corporation
12.6. DiaSorin SpA
12.7. Becton, Dickinson and Company
12.8. Danaher Corporation (Cepheid)
12.9. Savyon Diagnostics Ltd
12.10. Trinity Biotech Plc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Bio-Rad Laboratories, Inc, 4.	Key Developments, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc, Quidel Corporation, DiaSorin SpA, Becton, Dickinson and Company, Danaher Corporation (Cepheid), Savyon Diagnostics Ltd, Trinity Biotech Plc

표 목록 (Tables)

List of Tables

Table 1 Global Chlamydia Infection Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Chlamydia Infection Diagnostics Market Value, By Infection Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Chlamydia Infection Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Chlamydia Infection Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Chlamydia Infection Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 7 Global Chlamydia Infection Diagnostics Market Value, By Infection Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 9 Global Chlamydia Infection Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Chlamydia Infection Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Chlamydia Infection Diagnostics Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 14 North America Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 15 North America Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Chlamydia Infection Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Chlamydia Infection Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 22 Europe Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 23 Europe Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Chlamydia Infection Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 26 South America Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 27 South America Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 South America Chlamydia Infection Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Chlamydia Infection Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Chlamydia Infection Diagnostics Market Value, By Infection Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Chlamydia Infection Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Chlamydia Infection Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Bio-Rad Laboratories, Inc: Overview

Table 34 Bio-Rad Laboratories, Inc: Product Portfolio

Table 35 Bio-Rad Laboratories, Inc: Key Developments

Table 36 Abbott Laboratories: Overview

Table 37 Abbott Laboratories: Product Portfolio

Table 38 Abbott Laboratories: Key Developments

Table 39 F. Hoffmann-La Roche Ltd: Overview

Table 40 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 41 F. Hoffmann-La Roche Ltd: Key Developments

Table 42 Hologic, Inc: Overview

Table 43 Hologic, Inc: Product Portfolio

Table 44 Hologic, Inc: Key Developments

Table 45 Quidel Corporation: Overview

Table 46 Quidel Corporation: Product Portfolio

Table 47 Quidel Corporation: Key Developments

Table 48 DiaSorin SpA: Overview

Table 49 DiaSorin SpA: Product Portfolio

Table 50 DiaSorin SpA: Key Developments

Table 51 Becton, Dickinson and Company: Overview

Table 52 Becton, Dickinson and Company: Product Portfolio

Table 53 Becton, Dickinson and Company: Key Developments

Table 54 Danaher Corporation (Cepheid): Overview

Table 55 Danaher Corporation (Cepheid): Product Portfolio

Table 56 Danaher Corporation (Cepheid): Key Developments

Table 57 Savyon Diagnostics Ltd: Overview

Table 58 Savyon Diagnostics Ltd: Product Portfolio

Table 59 Savyon Diagnostics Ltd: Key Developments

Table 60 Trinity Biotech Plc: Overview

Table 61 Trinity Biotech Plc: Product Portfolio

Table 62 Trinity Biotech Plc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 2 Global Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 3 Global Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 4 Global Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 5 Global Chlamydia Infection Diagnostics Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Chlamydia Infection Diagnostics Market Y-o-Y Growth, By Test Type, 2023-2031 (%)

Figure 7 Nucleic Acid Amplification Test (NAAT) Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 8 Culture Tests Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 9 Direct Fluorescent Antibody Test Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 10 Serology Tests Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 11 Others Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 12 Global Chlamydia Infection Diagnostics Market Y-o-Y Growth, By Infection Type, 2023-2031 (%)

Figure 13 Genital Chlamydia Infection Infection Type in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 14 Rectal Chlamydia Infection Infection Type in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 15 Ocular Chlamydia Infection Infection Type in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 16 Global Chlamydia Infection Diagnostics Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 17 Hospitals End-User in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 18 Diagnostic Centers End-User in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 19 Specialty Clinics End-User in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 20 Others End-User in Global Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 21 Global Chlamydia Infection Diagnostics Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 22 North America Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 23 North America Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 24 North America Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 25 North America Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 26 North America Chlamydia Infection Diagnostics Market Share, By Country, 2023 & 2031 (%)

Figure 27 Asia-Pacific Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 28 Asia-Pacific Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 29 Asia-Pacific Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 30 Asia-Pacific Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 31 Asia-Pacific Chlamydia Infection Diagnostics Market Share, By Country, 2023 & 2031 (%)

Figure 32 Europe Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 33 Europe Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 34 Europe Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 35 Europe Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 36 Europe Chlamydia Infection Diagnostics Market Share, By Country, 2023 & 2031 (%)

Figure 37 South America Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 38 South America Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 39 South America Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 40 South America Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 41 South America Chlamydia Infection Diagnostics Market Share, By Country, 2023 & 2031 (%)

Figure 42 Middle East and Africa Chlamydia Infection Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 43 Middle East and Africa Chlamydia Infection Diagnostics Market Share, By Test Type, 2023 & 2031 (%)

Figure 44 Middle East and Africa Chlamydia Infection Diagnostics Market Share, By Infection Type, 2023 & 2031 (%)

Figure 45 Middle East and Africa Chlamydia Infection Diagnostics Market Share, By End-User, 2023 & 2031 (%)

Figure 46 Bio-Rad Laboratories, Inc: Financials

Figure 47 Abbott Laboratories: Financials

Figure 48 F. Hoffmann-La Roche Ltd: Financials

Figure 49 Hologic, Inc: Financials

Figure 50 Quidel Corporation: Financials

Figure 51 DiaSorin SpA: Financials

Figure 52 Becton, Dickinson and Company: Financials

Figure 53 Danaher Corporation (Cepheid): Financials

Figure 54 Savyon Diagnostics Ltd: Financials

Figure 55 Trinity Biotech Plc: Financials

세계 클라미디아 감염 진단 시장 – 2024-2031년

Global Chlamydia Infection Diagnostics Market - 2024-2031